Deciphera Pharmaceuticals has concluded its target enrolment in the Phase III clinical study analysing its switch-control tyrosine kinase inhibitor, Qinlock (ripretinib), in patients with second-line gastrointestinal stromal tumour (GIST).

Qinlock is designed to broadly stop KIT and PDGFRA mutated kinases deploying a dual mechanism of action that regulates the kinase switch pocket and activation loop.

GIST is a cancer that affects the digestive tract or nearby structures within the abdomen and is commonly seen in the stomach or small intestine.

The randomised, global, multi-centre, open-label INTRIGUE study will analyse the efficacy and safety of Qinlock versus sunitinib in patients with GIST previously treated with imatinib.

Around 426 patients will randomly receive either Qinlock 150mg once daily or sunitinib 50mg once daily for four weeks. This will be followed by two weeks without sunitinib.

Median progression-free survival (mPFS), as determined by independent radiologic review using the modified Response Evaluation Criteria in Solid Tumors (RECIST) scale, will be the trial’s primary efficacy endpoint.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Secondary endpoints of the study include objective response rate (ORR) and overall survival (OS).

Deciphera Pharmaceuticals executive vice-president and chief medical officer Matthew Sherman said: “We are pleased to announce the completion of target enrollment for our Phase III INTRIGUE study in patients with second-line GIST.

“This marks an important step forward to potentially bringing QINLOCK to an early-stage GIST population and establishing QINLOCK as the best-in-class treatment for this disease.”

At present, the study is being carried out at 122 investigational sites in 22 countries.

Deciphera plans to announce top-line results for the study in the second half of next year.

Qinlock is currently approved in the US, Canada, and Australia for treating adult patients with advanced GIST who have received prior treatment with three or more kinase inhibitors.